Table 1.
Significant Characteristics of Selected Manuscripts
| Group | First Author; Year | Anti-PD-1 (µg/dose); Route | Dosing (days after tumor innoculation) | Anti-PD-1 Clone; Vendor | Tumor Inoculation (# cells; volume; depth) | Mice (sex; weeks old; vendor) | % LTS | Median Survival (Sham; anti-PD1) (days) | Ctrl. |
|---|---|---|---|---|---|---|---|---|---|
| A | Belcaid; 2020 | 200 µg/dose; I.P. | 7, 9, 11 | G4; PIH | 50 000 GL261; NA; 3 mm | F; 6–8; Harlan | 0% | (NA; 22.5) | IgG |
| A | Dai; 2018 | 200 µg/dose; I.P. | 2, 4, 6b | RMP1-14; BioXCell | 50 000 GL261; 5 µL; 1.5 mm | M; 6–8; CMCYU | 0% | NA | Saline |
| A | Galstyan; 2019 | 200 µga/dose; I.V. | 8, 13, 16, 20, 23, 27 | J43; BioXCell | 20 000 GL261; 2 µL; NA | F; 8; JL | 0% | NA | PBS |
| A | Kim; 2019 | 200 µg/dose; I.P. | 8, 13, 16, 29, 23, 26 | RMP1-14; BioXCell | 200 000 GL261; 3 µL; 3.5 mm | F; 6; CRL | 0% | (19; 21) | Untreated |
| B | Hardcastle; 2017 | 200 µg/dose; I.P. | 6, 8, 14 | RMP1-14; BioLegend | 300 000 GL261; NA; NA | NA; NA; CRL | 0% | NA | Untreated |
| B | Lamano; 2019 | 250 µg/dose; I.P. | 7, 10, 13, 16, 19, 22, 25, 28 | RMP1-14; BioXCell | 300 000 Gl261; 2 µL; 3 mm | NA; 7–8; JL | 0% | (19; 30.5) | IgG |
| B | Shevtsov; 2019 | 250 µg/dose; I.P. | 6, 9, 12, 15 | RMP1-30; eBioscience | 100 000 GL261; 2 µL; 3 mm | M; 8–10; RAMS | 0% | NA | PBS/IgG |
| B | Zeng; 2013 | 200 µga/dose; I.P. | 10, 12, 14 | G4; PIH | 130 000 Gl261-Luc; 1 µL; 3 mm | F; 6–8; JL | 0% | (26; 30) | IgG |
| C | Dejaegher; 2017 | 200 µg/dose; I.P. | 5, 10, 15 | RMP1-14c; PIH | 500 000 GL261; 10 µL; 3m m | F; 8–10; Envigo | 55% | (24.5; NA) | IgG |
| C | Hung; 2018 | 200 µg/dose; I.P. | 10, 12, 14 | 4 H2; Bristol-Myers Squibb | 130 000 GL261-Luc; 1 µL; 3 mm | F; 6–8; JL | 14.3% | (25; 34) | Untreated |
| C | Jahan; 2019 | 200 µg/dose; I.P. | 3, 6, 9 | RMP1-14; BioXCell | 75 000 GL261; 3 µL; 2.5 mm | F; 6–7; NCI | 20% | NA | IgG |
| C | Karachi; 2019 | 200 µga/dose; I.P. | 7, 12, 17, 22b | RMP1-14; BioXCell | NA; NA; 4 mm | NA; NA; JL | 50% | NA | Untreated |
| C | Kim; 2017 | 200 µg/dose; NA | 10, 12, 14 | G4; PIH | 130 000 GL261-Luc; 1 µL; 3 mm | F; 6–8; JHUAF | 27.8% | (22; 33) | Unspec. |
| C | Mathios; 2016 | 200 µg/dose; I.P. | 10, 12, 14 | G4; PIH | 130 000 GL261-Luc; 1 µL; 3 mm | F; 6–8; JL | 20% | (16; 25.5) | PBS |
| C | Speranza; 2018 | 200 µg/dose; I.P. | 10, 13, 16, 19 | 29F.1A12; PIH | 100 000 GL261-Luc; 5 µL; 3 mm | F; 6–8; Envigo | 50% | NA | Unspec. |
| C | Wu; 2019 | 200 µg/dose; I.P. | 10, 12, 14 | NA; Bristol-Myers Squibb | 130 000 GL261-Luc; 1 µL; 3 mm | F; 6–8; JL | 30% | (24; 30) | Untreated |
I.P., intraperitoneal; I.V., intravenous; NA, not applicable/data not provided in manuscript; PIH, antibodies that are “Produced In House” from a cultured hybridoma; CMCYU, Comparative Medical Center of Yangzhou University; JL, The Jackson Laboratory; CRL, Charles River Laboratories; RAMS, Russian Academy of Medical Sciences; JHUAF, Johns Hopkins University Animal Facility; LTS, long-term survivors; Ctrl., nature of control group; Unspec., the control group of unspecified nature.
Experimental parameters of the selected studies are listed. For ease of comparison, each publication has been assigned to a group based on the survival benefit the authors declared anti-PD-1 CBI monotherapy to provide for GL261 glioma-bearing animals. The groups are as follows: (A) No increase in survival as a result of therapeutic intervention, (B) some increase in survival but no long-term survivors, and (C) a survival benefit and some number of long-term survivors following therapy. Within groups, manuscripts are arranged alphabetically by the last name of the first author.
aDemarcates doses of anti-PD-1 that were written as 10 mg/kg in the study in question. For ease of comparison with studies that administered a consistent amount (µg) of anti-PD-1 regardless of mouse weight, these scaled doses have been standardized assuming a weight of 20 g, which would not be unusual for a young female C57BL/6 mouse.
bDemarcates a dosing timecourse where significant ambiguity existed in the original manuscript and we were forced to draw an inference regarding the methods.
cThis manuscript listed the clone used as “RPMI-14,” but, as no corroborating evidence as to the existence of this clone could be found, we have made the assumption that the authors intended to write “RMP1-14” which is a commonly used clone of anti-PD-1 antibody.